Introduction: Cardiovascular disease is a poorly recognized problem in systemic lupus erythematosus (SLE) patients, who may have their disease activity associated with cardiac disease at the time of diagnosis or at a later stage of the course of disease. Manifestations are variable, as all structures of the heart can be affected, and can cause significant morbidity and mortality. Objective: The presentation may vary from subclinical form to advanced stages, which require aggressive immunosuppressive therapy. A description is presented of the frequency of these manifestations in patients with systemic lupus erythematosus attending a reference institution of Cundinamarca, Colombia. Methods: A retrospective study was conducted with the recording of clinical aspects, laboratory tests, and cardiovascular manifestations over a period of one year. Results: The study included a total of 45 patients with confirmed diagnosis of SLE, with a mean age of 35 years. Deterioration in functional class and dyspnea occurred more frequently.A positive anti-DNA was more frequent in patients with dyspnea (p=.037) and impaired functional class (p=.023). The lupus anticoagulant is also present in patients with deep venous thrombosis (60 vs. 15%; p=.018), and in patients with heart failure (66 vs. 16%: p=.036). Conclusion: Cardiovascular symptoms are present in a high percentage of patients with SLE, thus these should be questioned to in order to detect them earlier and avoid cardiovascular complications. It is suggested that some autoantibodies, as anti-DNA, lupus anticoagulant, low plasma complement, and anti-C1q, could also be useful for detecting new cardiovascular events in patients with SLE.
V., P. I., E., M., & J., L. (2015). Cardiovascular manifestations in patients with systemic lupus erythematosus during a one-year period in an institution in Cundinamarca, Colombia. Revista Colombiana de Reumatologia, 22(2), 84–89. Retrieved from http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L605517554